Login to Your Account



Washington Roundup

Biosimilar Path Expected to Be Under Construction for Years

By Mari Serebrov
Washington Editor

Friday, February 8, 1991
WASHINGTON – The Congressional Research Service (CRS) has a few words for those hoping to use the new biosimilar pathway as a shortcut to cash in quickly on the high price of biologics. Be patient. And watch out. This new road could be under construction for a long time.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription